TY  - JOUR
AU  - Cattrini, Carlo
AU  - Castro, Elena
AU  - Lozano, Rebeca
AU  - Zanardi, Elisa
AU  - Rubagotti, Alessandra
AU  - Boccardo, Francesco
AU  - Olmos, David
PY  - 2019
DO  - 10.3390/cancers11091355
SN  - 2072-6694
UR  - http://hdl.handle.net/10668/14537
T2  - Cancers
AB  - The possible treatments options for metastatic hormone-sensitive prostate cancer (mHSPC) have dramatically increased during the last years. The old backbone, which androgen-deprivation therapy (ADT) is the exclusive approach for hormone-naïve...
LA  - en
PB  - MDPI
KW  - Abiraterone acetate
KW  - Apalutamide
KW  - Docetaxel
KW  - Enzalutamide
KW  - Hormone-naïve prostate cancer
KW  - Hormone-sensitive prostate cancer
KW  - Radiotherapy
KW  - Prostatic Neoplasms
KW  - Abiraterone Acetate
KW  - Androgen Antagonists
KW  - Sample Size
KW  - Biomarkers
TI  - Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer.
TY  - research article
VL  - 11
ER  -